MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
Arbutus Biopharma Corporation EV - Enterprise Value 2011-2026 | ABUS
Annual EV - Enterprise Value Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 847 M | 818 M | 457 M | 449 M | 339 M | 283 M | 160 M | 196 M | 279 M | 185 M | 141 M | 533 M | 143 M | 31 M | 23.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 847 M | 23.8 M | 326 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aligos Therapeutics
ALGS
|
82.6 M | $ 7.92 | -0.94 % | $ 78.3 M |  USA |
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Precision BioSciences
DTIL
|
74.1 M | $ 6.73 | 0.9 % | $ 25.9 M | USA |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
1.16 B | $ 2.15 | -0.69 % | $ 447 M | USA |
 |
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.81 | -0.33 % | $ 27.9 M |  Israel |
 |
BioNTech SE
BNTX
|
-4.91 B | $ 97.86 | 2.47 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 20.29 | -0.39 % | $ 948 M | USA |
 |
Galectin Therapeutics
GALT
|
306 M | $ 2.42 | 5.22 % | $ 155 M | USA |
 |
Genmab A/S
GMAB
|
27 B | $ 28.24 | -0.04 % | $ 18 B |  Danmark |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Grifols, S.A.
GRFS
|
11.8 B | $ 8.14 | -0.85 % | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
GT Biopharma
GTBP
|
-2.9 M | $ 0.36 | -3.5 % | $ 1.98 M | USA |
 |
Halozyme Therapeutics
HALO
|
12 B | $ 67.79 | -0.05 % | $ 8.12 B | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
493 M | $ 1.42 | 1.07 % | $ 365 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.96 | 1.37 % | $ 4.87 M | Israel |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
540 M | $ 4.15 | 1.72 % | $ 444 M | USA |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 24.3 | 0.37 % | $ 3.09 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.26 B | $ 28.82 | -0.24 % | $ 1.66 B | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.07 B | $ 32.37 | 0.4 % | $ 2.15 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.52 | 1.68 % | $ 405 M | Britain |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
9.99 M | - | - | $ 1.41 B | USA |
 |
ImmuCell Corporation
ICCC
|
69.7 M | $ 7.24 | 2.33 % | $ 65.3 M | USA |
 |
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | USA |
|
Immatics N.V.
IMTX
|
503 M | $ 10.61 | 1.73 % | $ 668 M | Germany |
 |
Incyte Corporation
INCY
|
18.2 B | $ 96.66 | 0.61 % | $ 18.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-15.2 M | $ 2.58 | 1.18 % | $ 16.2 M | USA |
 |
InflaRx N.V.
IFRX
|
-2.36 M | $ 1.05 | 4.95 % | $ 152 M | Germany |